closedosingdownloadefficacymoasafetytable-checktable-cross

The OTEZLA® international website

This site is intended for healthcare professionals outside the U.S.

OTEZLA IS THE ONLY ORAL PDE4 INHIBITOR APPROVED FOR PSORIASIS AND PSORIATIC ARTHRITIS1

Targeting key intracellular signals to reduce inflammation2

  • Through intracellular PDE4 inhibition, OTEZLA reduces production of pro-inflammatory mediators and boosts production of anti-inflammatory mediators2
  • These mediators are implicated in the pathogenesis of psoriasis and psoriatic arthritis1,2

OTEZLA has broad effects on the cytokines involved in multiple manifestations of psoriatic arthritis1

PDE4 is a key inflammatory mediator

  • PDE4 is active in immune cells, keratinocytes, and synovial cells
  • PDE4 converts cAMP to AMP, which increases inflammatory signaling

OTEZLA is an oral PDE4 inhibitor

  • Blocking PDE4 maintains intracellular cAMP levels higher than AMP
  • Higher levels of cAMP help lead to balanced immune signaling

Blocking PDE4 helps regulate immune signaling

  • Decreased production of pro-inflammatory mediators
  • Increased production of anti-inflammatory mediators
Phosphodiesterase 4
Adenosine monophosphate
Cyclic adenosine monophosphate

Impact of OTEZLA on production of selected cytokines3

Watch the video

References:

  1. OTEZLA Summary of Product Characteristics. Stockley Park, Uxbridge, UK: Celgene Europe, Ltd; 2017.
  2. Schafer PH, Parton A, Capone L, et al. Apremilast is a selective PDE4 inhibitor with regulatory effects on innate immunity. Cell Signal. 2014;26(9):2016-2029.
  3. Schafer PH, Chen P, Fang L, et al. The pharmacodynamic impact of apremilast, an oral phosphodiesterase 4 inhibitor, on circulating levels of inflammatory biomarkers in patients with psoriatic arthritis: substudy results from a phase III, randomized, placebo-controlled trial (PALACE 1). J Immunol Res. 2015;2015(1):1-10.
You are leaving the OTEZLA® (apremilast) website
Do you wish to leave this site?
OTEZLA International Websites
OTEZLA is approved in 51 Countries
  • United States

  • Canada

  • Australia

  • Israel

  • Switzerland

  • New Zealand

  • Austria

  • Belgium

  • Bulgaria

  • Croatia

  • Republic of Cyprus

  • Czech Republic

  • Denmark

  • Estonia

  • Finland

  • France

  • Germany

  • Greece

  • Hungary

  • Ireland

  • Italy

  • Latvia

  • Lithuania

  • Luxembourg

  • Malta

  • Netherlands

  • Poland

  • Portugal

  • Romania

  • Slovakia

  • Slovenia

  • Spain

  • Sweden

  • United Kingdom

  • Norway

  • Iceland

  • Liechtenstein

  • Russia

  • Japan

  • Hong Kong

  • Singapore

  • Kuwait

  • Taiwan

  • UAE

  • Korea

  • Thailand

  • Lebanon

  • Qatar

  • Argentina

  • Mexico

  • Brazil